Weight-loss jabs push sugar price to five-year low
Futures price has fallen to less than half its level in late 2023 as GLP-1s reduce cravings for sweet snacks
Related reading
China to drive a weight-loss drug price war
The active ingredient semaglutide is starting to lose patent protection and China can produce GLP-1 related treatments at scale
Weight-loss drugs are bringing a new commercial reality
The reinforcing feedback loop that has long powered the food industry is being chemically switched off
Off the Scales — the impact of weight-loss jabs, from our bodies to the pharma…
Focusing on Novo Nordisk, Aimee Donnellan’s book ranges across R&D, patents, medical effects and the stigma attached to obesity
Eli Lilly’s weight-loss pill meets target in key diabetes trial
Results from US pharma group show oral drug reduced body weight by 10.5% on average
Indian weight-loss market becomes ‘bloodbath’ as drugmakers pile in
Consumers await cheaper generics after expiry of patent for Ozempic ingredient
How GLP-1s changed Thanksgiving
Obesity medications are diminishing appetites for the foods that American holidays are known for